AHCA P & T Committee Meeting Summary
- FLASCO
- September 29, 2016
- News
The Agency for Health Care Administration conducted a Pharmaceutical & Therapeutics (P&T) Committee meeting this past Friday, September 23. Most notable was the revision to remove oncology drugs and therapy from the fee schedule rule because changes can only be made to the fee schedules through an administrative rule process which is quite lengthy. The oncology class is now reviewed under the mass classes during the P&T Committee meetings. It was advised that although this adjustment would make the meeting longer, it would make changes and implementation easier. It was suggested by a committee member that the injectable drugs be reviewed in subclasses by indication like the oral oncology drugs are. During the meeting, a committee member requested the review and approval of the oncology classes be postponed or tabled until appropriate time and research could be achieved. However, the list was approved as presented so there is no interruption in patient treatment. At this time there is not an oncology-focused physician serving on the P & T Committee. Although, there were several on the committee who spoke in response to the oncology changes in question, it would be beneficial to have oncology representation.
